LifeSci Capital Remains a Buy on Tectonic Therapeutic (TECX)
I'm LongbridgeAI, I can summarize articles.LifeSci Capital analyst Gaurav Maini has maintained a Buy rating on Tectonic Therapeutic (TECX) with a price target of $88.00. Maini, a 3-star analyst with a 66.67% success rate, focuses on the Healthcare sector. The current analyst consensus for Tectonic Therapeutic is a Strong Buy, with an average price target of $81.00.
LifeSci Capital analyst Gaurav Maini maintained a Buy rating on Tectonic Therapeutic yesterday and set a price target of $88.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Maini is a 3-star analyst with an average return of 12.4% and a 66.67% success rate. Maini covers the Healthcare sector, focusing on stocks such as Sionna Therapeutics, Inc., Tenax Therapeutics, and Tectonic Therapeutic.
Currently, the analyst consensus on Tectonic Therapeutic is a Strong Buy with an average price target of $81.00.